^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GB235

    i
    Other names: GB235
    Associations

    News

    Trials
    Company:
    Walvax
    Drug class:
    HER2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4years
    A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo. (PubMed, Sci Rep)
    In a Trastuzumab-resistant patient-derived tumor xenograft model GA0060, GB235 plus Trastuzumab reversed the resistance to Trastuzumab monotherapy. Because GB235 showed a different working mechanism with Pertuzumab and Trastuzumab, these agents can be considered complementary therapy against HER2 overexpression tumors.
    Preclinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 positive • HER-2 overexpression • HER-2 expression
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • GB235 • trastuzumab biosimilar